Three months on, Eli Lilly has closed the books on its search for a new chief financial officer. And as with its previous CFO ...
Zacks.com on MSN4d
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...
The original concerns of the US regulatory agency over the manufacturing of Eli Lilly’s Ebglyss seem to have been resolved, ...
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
Zacks.com on MSN10d
Bull of the Day: Eli Lilly (LLY)Eli Lilly ( LLY) has long been a reliable name in the healthcare sector, providing stability for investors during periods of ...
Zacks.com on MSN5d
Lilly Gets FDA Approval for Eczema Drug EbglyssEli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for ...
Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U ...
On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and ... The drug is ...
In addition, Eli Lilly has still refused to lower the outrageous ... United States but just $485 in the United Kingdom and $94 in Japan. And let’s be clear: Even with this modest price reduction ...
Pharmaceutical Technology on MSN6d
Lilly’s EBGLYSS gains FDA approval for patients aged 12 and olderEli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12 ...
Shortly after a positive data drop for Eli Lilly’s efsitora a | Lilly revealed that its weekly insulin candidate efsitora ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback